News & Events

News & Events

Recent News

Ortho Clinical Diagnostics Expands Therapeutic Drug Assay Menu in Collaboration With Thermo Fisher Scientific

Oct 8, 2019

Ortho, in collaboration with Thermo Fisher Scientific, has expanded the menus on MicroTip-capable VITROS® Systems to enable testing for digitoxin, a widely prescribed cardiac medication, and tricyclic antidepressants (TCAs) -- both drugs that can pose a danger if taken outside prescribed dosage levels.

Chris Smith Named Next Chief Executive Officer of Ortho Clinical Diagnostics

Aug 27, 2019

Ortho's board of directors has appointed Chris Smith as CEO effective Sept. 9, 2019. He will succeed Robert Yates, who is stepping down as CEO but will continue to serve as Ortho’s non-executive chairman as a member of the board of directors.

Ortho Receives CE Mark for Enhanced VITROS® Immunodiagnostic Products NT-proBNP II Assay, an Aid in Diagnosing and Assessing Heart Failure

Jul 23, 2019

The analytical characteristics and clinical performance of the VITROS NT-proBNP II assay allow clinicians to efficiently assess heart failure patients.

© Ortho Clinical Diagnostics 2019. Ortho Clinical Diagnostics, publishes this site and is solely responsible for its content. The availability of the products is subject to compliance with the regulatory requirements of each market.